Education
About Us
Working with TipRanks
Follow Us
Sangamo Biosciences (SGMO)
NASDAQ:SGMO
Total Valuation
Sangamo Biosciences has a market cap or net worth of $130.06M. The enterprise value is $144.15M.
Market Cap$130.06M
Enterprise Value$144.15M
Share Statistics
Sangamo Biosciences has 245,401,980 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding245,401,980
Owned by Insiders2.39%
Owned by Institutions0.18%
Financial Efficiency
Sangamo Biosciences’s return on equity (ROE) is -4.30 and return on invested capital (ROIC) is -172.58%.
Return on Equity (ROE)-4.30
Return on Assets (ROA)-0.96
Return on Invested Capital (ROIC)-172.58%
Return on Capital Employed (ROCE)-1.86
Revenue Per Employee315.85K
Profits Per Employee-535.20K
Employee Count183
Asset Turnover0.57
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Sangamo Biosciences is ―. Sangamo Biosciences’s PEG ratio is ―.
PE Ratio―
PS Ratio0.00
PB Ratio0.00
Price to Fair Value9.04
Price to FCF0.00
Price to Operating Cash Flow-2.35
PEG Ratio―
Income Statement
In the last 12 months, Sangamo Biosciences had revenue of 57.80M and earned -97.94M in profits. Earnings per share was -0.49.
Revenue57.80M
Gross Profit57.80M
Operating Income-103.97M
Pretax Income-98.11M
Net Income-97.94M
EBITDA-89.09M
Earnings Per Share (EPS)-0.49
Cash Flow
In the last 12 months, operating cash flow was -44.63M and capital expenditures -152.00K, giving a free cash flow of -44.89M billion.
Operating Cash Flow-44.63M
Free Cash Flow-44.89M
Free Cash Flow per Share-0.18
Dividends & Yields
Sangamo Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.43
52-Week Price Change-47.83%
50-Day Moving Average0.51
200-Day Moving Average1.10
Relative Strength Index (RSI)41.17
Average Volume (3m)5.35M
Important Dates
Sangamo Biosciences upcoming earnings date is Oct 30, 2025, After Close (Confirmed).
Last Earnings DateAug 7, 2025
Next Earnings DateOct 30, 2025
Ex-Dividend Date―
Financial Position
Sangamo Biosciences as a current ratio of 1.13, with Debt / Equity ratio of 507.05%
Current Ratio1.13
Quick Ratio1.13
Debt to Market Cap0.00
Net Debt to EBITDA0.13
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Sangamo Biosciences has paid -167.00K in taxes.
Income Tax-167.00K
Effective Tax Rate<0.01
Enterprise Valuation
Sangamo Biosciences EV to EBITDA ratio is -2.18, with an EV/FCF ratio of -2.88.
EV to Sales3.36
EV to EBITDA-2.18
EV to Free Cash Flow-2.88
EV to Operating Cash Flow-2.90
Balance Sheet
Sangamo Biosciences has $25.18M in cash and marketable securities with $24.88M in debt, giving a net cash position of -$304.00K billion.
Cash & Marketable Securities$25.18M
Total Debt$24.88M
Net Cash-$304.00K
Net Cash Per Share>-$0.01
Tangible Book Value Per Share$0.11
Margins
Gross margin is 95.96%, with operating margin of -179.88%, and net profit margin of -169.45%.
Gross Margin95.96%
Operating Margin-179.88%
Pretax Margin-169.74%
Net Profit Margin-169.45%
EBITDA Margin-154.13%
EBIT Margin-170.33%
Analyst Forecast
The average price target for Sangamo Biosciences is $4.10, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$4.10
Price Target Upside754.17% Upside
Analyst ConsensusModerate Buy
Analyst Count6
Revenue Growth Forecast239.92%
EPS Growth Forecast79.41%